Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2 vs 3 Courses of Concurrent Cisplatin in High-Risk HNSCC
NCT06492460Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2024
- Primary completion
- Sep 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Failure-free survival at 3 years. Started Sep 2024; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06492460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492460.